Critical Assessment Found CB1 Blockers Were No Better Than Existing Weight Loss Drugs
Despite promising mechanisms, CB1 receptor antagonists like rimonabant achieved weight loss comparable to existing anti-obesity medications while carrying potentially severe psychiatric side effects.
Quick Facts
What This Study Found
This critical review assessed how close CB1 cannabinoid receptor antagonists were to being ideal anti-obesity drugs.
The mechanisms were sound: CB1 antagonists reduced food intake centrally (brain) and may increase energy expenditure peripherally (thermogenesis in animal studies).
However, the clinical reality was disappointing. Despite these dual mechanisms, the weight loss achieved by rimonabant and taranabant (the two most advanced compounds) did not exceed that of already-approved anti-obesity medications.
More concerning, both compounds were associated with potentially severe psychiatric adverse effects including depression, anxiety, and suicidal ideation, which significantly limited their clinical utility.
The review noted several new CB1 antagonists in development and questioned whether they would differ meaningfully in efficacy and safety.
Key Numbers
Rimonabant and taranabant: weight loss did not exceed existing medications. Psychiatric adverse effects limited clinical use. Multiple new CB1 antagonists in development at the time.
How They Did This
Critical narrative review of CB1 receptor antagonist mechanisms of action, clinical trial efficacy data, and safety profiles, compared to existing approved anti-obesity medications.
Why This Research Matters
This review provided a reality check on the anti-obesity cannabinoid approach. While the mechanism was elegant, the clinical outcomes were underwhelming and the safety concerns were serious, leading to rimonabant's withdrawal and the shelving of other programs.
The Bigger Picture
This critical assessment foreshadowed rimonabant's market withdrawal in 2008 and the subsequent termination of taranabant's development. The field has since shifted toward peripherally restricted CB1 antagonists that may avoid brain-mediated psychiatric effects.
What This Study Doesn't Tell Us
Published during a period of active drug development, so the review could not assess compounds that were not yet in clinical trials. The comparison to existing anti-obesity drugs depended on the specific comparators chosen.
Questions This Raises
- ?Can peripherally restricted CB1 antagonists achieve meaningful weight loss without psychiatric risks?
- ?Is the endocannabinoid system the right target for obesity, or are the psychiatric risks inherent to CB1 modulation?
Trust & Context
- Key Stat:
- CB1 antagonist weight loss did not exceed existing medications; psychiatric side effects limited use
- Evidence Grade:
- This is a critical review synthesizing clinical trial data, providing a moderate evidence-based assessment of the CB1 antagonist approach to obesity.
- Study Age:
- Published in 2009. Rimonabant was withdrawn in 2008 and taranabant development was stopped. Newer peripherally restricted approaches are still being investigated.
- Original Title:
- A critical review of the cannabinoid receptor as a drug target for obesity management.
- Published In:
- Obesity reviews : an official journal of the International Association for the Study of Obesity, 10(1), 58-67 (2009)
- Authors:
- Akbas, F, Gasteyger, C, Sjödin, A, Astrup, A, Larsen, T M
- Database ID:
- RTHC-00343
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Why don't CB1 blockers work better for weight loss?
The body has multiple redundant appetite regulation systems. Blocking one (the endocannabinoid system) may not produce dramatic weight loss because other systems compensate. The brain also resists weight loss through various adaptive mechanisms.
Are there any cannabinoid-based weight loss drugs available?
No. Rimonabant was the only approved CB1 blocker and was withdrawn in 2008 due to psychiatric side effects. No replacement has been approved. The field is exploring peripherally restricted compounds that may avoid brain-related side effects.
Read More on RethinkTHC
- cannabis-cardiovascular-heart-risk-stroke
- cannabis-heart-cardiovascular-risk
- coughing-up-stuff-after-quitting-weed
- lung-recovery-after-quitting-smoking-weed
- lung-recovery-quitting-weed
- quitting-weed-female-hormones
- quitting-weed-weight-gain-loss-diet-appetite
- sex-after-quitting-weed
- weed-DUI-driving-impaired-cannabis-laws
- weed-acne-skin
- weed-fertility-sperm
- weed-gut-digestion-problems
- weed-heart-health
- weed-testosterone-levels
- why-does-weed-make-you-hungry-munchies
- why-does-weed-make-food-taste-better
Cite This Study
https://rethinkthc.com/research/RTHC-00343APA
Akbas, F; Gasteyger, C; Sjödin, A; Astrup, A; Larsen, T M. (2009). A critical review of the cannabinoid receptor as a drug target for obesity management.. Obesity reviews : an official journal of the International Association for the Study of Obesity, 10(1), 58-67. https://doi.org/10.1111/j.1467-789X.2008.00520.x
MLA
Akbas, F, et al. "A critical review of the cannabinoid receptor as a drug target for obesity management.." Obesity reviews : an official journal of the International Association for the Study of Obesity, 2009. https://doi.org/10.1111/j.1467-789X.2008.00520.x
RethinkTHC
RethinkTHC Research Database. "A critical review of the cannabinoid receptor as a drug targ..." RTHC-00343. Retrieved from https://rethinkthc.com/research/akbas-2009-a-critical-review-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.